In placebo controlled trials over two years, the agents reduced the relapse rate by 30%; interferon beta reduced the rate at which new lesions were detected by magnetic resonance imaging by 50.80% and modestly slowed the accumulation of disability in relapsing remitting but not secondary progressive non.relapsing multiple sclerosis.